WASHINGTON (Diya TV) — Elizabeth Holmes, the founder of the now-defunct blood testing company Theranos, has asked President Donald Trump to release her from prison, even though she has nearly six years left before becoming eligible for freedom. The request has reignited public debate over one of Silicon Valley’s most notorious fraud cases.
Holmes, 41, sought a commutation of her prison sentence last year. The request remains under review, according to the U.S. Department of Justice’s Office of the Pardon Attorney. The White House declined to comment on the matter, and Holmes’ lawyers did not respond to media inquiries.
A federal jury convicted Holmes in 2022 on four counts of wire fraud and conspiracy. Prosecutors said she deceived investors by promoting false claims about Theranos’ blood-testing technology. The court sentenced her to 11 years and three months in prison and ordered her to pay $452 million in restitution.
A federal appeals court upheld both her conviction and sentence in February 2025. Holmes is currently serving her sentence at a minimum-security federal prison camp in Bryan, Texas. Under current terms, she is eligible for release in December 2031. If Trump commutes her sentence, Holmes would still have to pay restitution to the victims. A full presidential pardon, however, would eliminate that obligation.
Theranos rose to fame during the early 2010s. Holmes claimed the company could run dozens of medical tests using a single drop of blood from a finger prick. The idea promised faster results, lower costs, and less pain for patients.
Investors embraced the vision. Theranos attracted hundreds of millions of dollars from prominent backers. At its peak, the company reached a valuation of $9 billion. Forbes magazine estimated Holmes’ net worth at $4.5 billion in 2015. Behind the scenes, however, the technology did not work as promised. Prosecutors said Holmes knew the devices failed to deliver accurate results. Despite that knowledge, she continued to market the product and reassure investors.
During the trial, prosecutors showed evidence that Holmes misled investors from 2010 to 2015. She exaggerated the company’s capabilities and downplayed serious technical problems. Internal tests showed unreliable results, yet Holmes publicly claimed success.
The fraud cost investors hundreds of millions of dollars. While patients were not part of the criminal charges, the case raised concerns about public health risks and corporate accountability in the biotech industry. The collapse of Theranos became a cautionary tale. It highlighted the dangers of hype-driven startups and weak oversight in Silicon Valley.
Holmes submitted her commutation request while serving her sentence. The Office of the Pardon Attorney reviews such applications and provides recommendations to the president. There is no public timeline for a decision.
Trump has granted high-profile pardons and commutations in the past, often drawing criticism and praise in equal measure. Any decision regarding Holmes would likely spark strong reactions, given the scale of the fraud and the public attention surrounding her case. Legal experts note that commutations reduce prison time but do not erase convictions. Pardons, by contrast, forgive the crime entirely and can eliminate financial penalties.
Since entering prison, Holmes has kept a low public profile. She shares two young children with her partner, and her legal team has previously argued that her family situation warrants leniency. Judges rejected those arguments during sentencing. Holmes remains one of the most recognizable figures linked to corporate fraud in recent U.S. history. Her case continues to influence discussions about ethics, accountability, and regulation in the tech and health care sectors.
